American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors

Archit B. Baskaran; Priya Kumthekar; Amy B. Heimberger; Rimas V. Lukas

doi:10.2217/fon-2021-0955

American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors

Archit B. Baskaran, Priya Kumthekar, Amy B. Heimberger, Rimas V. Lukas^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.

Original language	English (US)
Pages (from-to)	4425-4429
Number of pages	5
Journal	Future Oncology
Volume	17
Issue number	33
DOIs	https://doi.org/10.2217/fon-2021-0955
State	Published - Nov 2021

Keywords

brain metastases
craniopharyngioma
glioblastoma
leptomeningeal metastases
meeting report
neuro-oncology

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2021-0955

Cite this

@article{f1a0c26d690d475b95b207373996cd50,

title = "American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors",

abstract = "In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.",

keywords = "brain metastases, craniopharyngioma, glioblastoma, leptomeningeal metastases, meeting report, neuro-oncology",

author = "Baskaran, {Archit B.} and Priya Kumthekar and Heimberger, {Amy B.} and Lukas, {Rimas V.}",

note = "Funding Information: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. NIH funding: Rimas V Lukas, Priya Kumthekar, and Amy B Heimberger are all supported by: P50 CA221747 (CA/NCI NIH HHS/United States). No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.",

year = "2021",

month = nov,

doi = "10.2217/fon-2021-0955",

language = "English (US)",

volume = "17",

pages = "4425--4429",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "33",

}

TY - JOUR

T1 - American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors

AU - Baskaran, Archit B.

AU - Kumthekar, Priya

AU - Heimberger, Amy B.

AU - Lukas, Rimas V.

N1 - Funding Information: The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. NIH funding: Rimas V Lukas, Priya Kumthekar, and Amy B Heimberger are all supported by: P50 CA221747 (CA/NCI NIH HHS/United States). No writing assistance was utilized in the production of this manuscript. Publisher Copyright: © 2021 Future Medicine Ltd.

PY - 2021/11

Y1 - 2021/11

N2 - In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.

AB - In this report, select key studies presented at the American Society of Clinical Oncology (ASCO) 2021 annual meeting are reviewed. Two major phase III randomized controlled trials were presented at the meeting: GEINO 1401 and EORTC 1709/CCTG CE.8. Both are reviewed in this report. Moreover, important phase II trials, including Alliance A0716701, and key phase I trials are included. All trials presented cover important advances in the understanding of primary brain tumor management. In addition, case series papers, trials in progress and select work on exploratory CSF biomarkers are reviewed. Altogether, research presented at ASCO 2021 highlights important advances in neuro-oncologic topics that may inform future research and practice.

KW - brain metastases

KW - craniopharyngioma

KW - glioblastoma

KW - leptomeningeal metastases

KW - meeting report

KW - neuro-oncology

UR - http://www.scopus.com/inward/record.url?scp=85118937853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118937853&partnerID=8YFLogxK

U2 - 10.2217/fon-2021-0955

DO - 10.2217/fon-2021-0955

M3 - Article

C2 - 34672682

AN - SCOPUS:85118937853

SN - 1479-6694

VL - 17

SP - 4425

EP - 4429

JO - Future Oncology

JF - Future Oncology

IS - 33

ER -

American Society of Clinical Oncology 2021 Annual Meeting updates on primary brain tumors and CNS metastatic tumors

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this